Florida CRO expands drug screening and manufacturing

By The Science Advisory Board staff writers

February 21, 2020 -- Florida-based contract research organization (CRO) Alchem Laboratories is constructing a new building to grow its screening and chemical trail manufacturing capabilities.

The new 12,000-sq-ft multiuse facility -- Building 3 -- will provide high-throughput screening, biologics and drug product manufacturing, and analytical support, according to Alchem. Scheduled to be completed by the end of 2020, the building will enable continued and expanded support for products in clinical studies, the company said. Alchem indicated that it will also initiate ISO 9001 certification to support current late-stage clinical trial and commercial manufacturing operations.

The firm is currently supporting seven different five-year contracts with the U.S. National Institutes of Health and the Department of Defense for screening and drug product manufacturing. In addition, Alchem said it has manufactured products in 20 active clinical programs as of the beginning of 2000.

Copyright © 2020 scienceboard.net

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
2nd Annual Cell Therapy Bioprocessing Conference
June 25-26
Boston, Massachusetts United States
BioProcess International Europe
July 13-16
Amsterdam, Noord-Holland Netherlands
Bioprocess International West
August 10-13
Santa Clara, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter